Skip to main content

Table 3 Best response by final daily dose of pomalidomide

From: A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Variable Final daily dose of pomalidomidea
4 mg (n = 27) 3 mg (n = 7) 2 mg (n = 2)
Best response rate, n (%)
 Overall response 12 (44.4) 3 (42.9) 0
  Complete response 1 (3.7) 0 0
  Very good partial response 0 0 0
  Partial response 11 (40.7) 3 (42.9) 0
 Stable disease 11 (40.7) 3 (42.9) 2 (100)
 Progressive disease 4 (14.8) 1 (14.3) 0
  1. aDaily dose as of February 3, 2015